These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 31727677)

  • 1. HIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance with PT2385, a First-in-Class HIF-2 Inhibitor, in Patients with Clear Cell Renal Cell Carcinoma.
    Courtney KD; Ma Y; Diaz de Leon A; Christie A; Xie Z; Woolford L; Singla N; Joyce A; Hill H; Madhuranthakam AJ; Yuan Q; Xi Y; Zhang Y; Chang J; Fatunde O; Arriaga Y; Frankel AE; Kalva S; Zhang S; McKenzie T; Reig Torras O; Figlin RA; Rini BI; McKay RM; Kapur P; Wang T; Pedrosa I; Brugarolas J
    Clin Cancer Res; 2020 Feb; 26(4):793-803. PubMed ID: 31727677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting renal cell carcinoma with a HIF-2 antagonist.
    Chen W; Hill H; Christie A; Kim MS; Holloman E; Pavia-Jimenez A; Homayoun F; Ma Y; Patel N; Yell P; Hao G; Yousuf Q; Joyce A; Pedrosa I; Geiger H; Zhang H; Chang J; Gardner KH; Bruick RK; Reeves C; Hwang TH; Courtney K; Frenkel E; Sun X; Zojwalla N; Wong T; Rizzi JP; Wallace EM; Josey JA; Xie Y; Xie XJ; Kapur P; McKay RM; Brugarolas J
    Nature; 2016 Nov; 539(7627):112-117. PubMed ID: 27595394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 3-[(1
    Xu R; Wang K; Rizzi JP; Huang H; Grina JA; Schlachter ST; Wang B; Wehn PM; Yang H; Dixon DD; Czerwinski RM; Du X; Ged EL; Han G; Tan H; Wong T; Xie S; Josey JA; Wallace EM
    J Med Chem; 2019 Aug; 62(15):6876-6893. PubMed ID: 31282155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma.
    Courtney KD; Infante JR; Lam ET; Figlin RA; Rini BI; Brugarolas J; Zojwalla NJ; Lowe AM; Wang K; Wallace EM; Josey JA; Choueiri TK
    J Clin Oncol; 2018 Mar; 36(9):867-874. PubMed ID: 29257710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting HIF-2 α in clear cell renal cell carcinoma: A promising therapeutic strategy.
    Martínez-Sáez O; Gajate Borau P; Alonso-Gordoa T; Molina-Cerrillo J; Grande E
    Crit Rev Oncol Hematol; 2017 Mar; 111():117-123. PubMed ID: 28259286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential effects of HIF2α antagonist and HIF2α silencing in renal cancer and sensitivity to repurposed drugs.
    Arnaiz E; Miar A; Bridges E; Prasad N; Hatch SB; Ebner D; Lawrie CH; Harris AL
    BMC Cancer; 2021 Aug; 21(1):896. PubMed ID: 34353313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ARNT-dependent HIF-2 transcriptional activity is not sufficient to regulate downstream target genes in neuroblastoma.
    Persson CU; von Stedingk K; Fredlund E; Bexell D; Påhlman S; Wigerup C; Mohlin S
    Exp Cell Res; 2020 Mar; 388(2):111845. PubMed ID: 31945318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIF-2alpha: Achilles' heel of pseudohypoxic subtype paraganglioma and other related conditions.
    Tella SH; Taïeb D; Pacak K
    Eur J Cancer; 2017 Nov; 86():1-4. PubMed ID: 28946040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PHGDH as a Key Enzyme for Serine Biosynthesis in HIF2α-Targeting Therapy for Renal Cell Carcinoma.
    Yoshino H; Nohata N; Miyamoto K; Yonemori M; Sakaguchi T; Sugita S; Itesako T; Kofuji S; Nakagawa M; Dahiya R; Enokida H
    Cancer Res; 2017 Nov; 77(22):6321-6329. PubMed ID: 28951458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and Activity of Specific Hypoxia-Inducible Factor-2α (HIF-2α) Inhibitors for the Treatment of Clear Cell Renal Cell Carcinoma: Discovery of Clinical Candidate ( S)-3-((2,2-Difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1 H-inden-4-yl)oxy)-5-fluorobenzonitrile (PT2385).
    Wehn PM; Rizzi JP; Dixon DD; Grina JA; Schlachter ST; Wang B; Xu R; Yang H; Du X; Han G; Wang K; Cao Z; Cheng T; Czerwinski RM; Goggin BS; Huang H; Halfmann MM; Maddie MA; Morton EL; Olive SR; Tan H; Xie S; Wong T; Josey JA; Wallace EM
    J Med Chem; 2018 Nov; 61(21):9691-9721. PubMed ID: 30289716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Small-Molecule Antagonist of HIF2α Is Efficacious in Preclinical Models of Renal Cell Carcinoma.
    Wallace EM; Rizzi JP; Han G; Wehn PM; Cao Z; Du X; Cheng T; Czerwinski RM; Dixon DD; Goggin BS; Grina JA; Halfmann MM; Maddie MA; Olive SR; Schlachter ST; Tan H; Wang B; Wang K; Xie S; Xu R; Yang H; Josey JA
    Cancer Res; 2016 Sep; 76(18):5491-500. PubMed ID: 27635045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allosteric inhibition of HIF-2α as a novel therapy for clear cell renal cell carcinoma.
    Yu Y; Yu Q; Zhang X
    Drug Discov Today; 2019 Dec; 24(12):2332-2340. PubMed ID: 31541711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models.
    Cho H; Du X; Rizzi JP; Liberzon E; Chakraborty AA; Gao W; Carvo I; Signoretti S; Bruick RK; Josey JA; Wallace EM; Kaelin WG
    Nature; 2016 Nov; 539(7627):107-111. PubMed ID: 27595393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic Profiling of the Novel Hypoxia-Inducible Factor 2
    Xie C; Gao X; Sun D; Zhang Y; Krausz KW; Qin X; Gonzalez FJ
    Drug Metab Dispos; 2018 Apr; 46(4):336-345. PubMed ID: 29363499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Attenuating hypoxia driven malignant behavior in glioblastoma with a novel hypoxia-inducible factor 2 alpha inhibitor.
    Renfrow JJ; Soike MH; West JL; Ramkissoon SH; Metheny-Barlow L; Mott RT; Kittel CA; D'Agostino RB; Tatter SB; Laxton AW; Frenkel MB; Hawkins GA; Herpai D; Sanders S; Sarkaria JN; Lesser GJ; Debinski W; Strowd RE
    Sci Rep; 2020 Sep; 10(1):15195. PubMed ID: 32938997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIF-independent synthetic lethality between CDK4/6 inhibition and VHL loss across species.
    Nicholson HE; Tariq Z; Housden BE; Jennings RB; Stransky LA; Perrimon N; Signoretti S; Kaelin WG
    Sci Signal; 2019 Oct; 12(601):. PubMed ID: 31575731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIF2α Antagonism Has Antitumor Activity in Advanced ccRCC.
    Cancer Discov; 2018 Feb; 8(2):OF6. PubMed ID: 29330266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis.
    Choueiri TK; Bauer TM; Papadopoulos KP; Plimack ER; Merchan JR; McDermott DF; Michaelson MD; Appleman LJ; Thamake S; Perini RF; Zojwalla NJ; Jonasch E
    Nat Med; 2021 May; 27(5):802-805. PubMed ID: 33888901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans.
    Ma Y; Joyce A; Brandenburg O; Saatchi F; Stevens C; Toffessi Tcheuyap V; Christie A; Do QN; Fatunde O; Macchiaroli A; Wong SC; Woolford L; Yousuf Q; Miyata J; Carrillo D; Onabolu O; McKenzie T; Mishra A; Hardy T; He W; Li D; Ivanishev A; Zhang Q; Pedrosa I; Kapur P; Schluep T; Kanner SB; Hamilton J; Brugarolas J
    Clin Cancer Res; 2022 Dec; 28(24):5405-5418. PubMed ID: 36190432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting HIF2α in Clear-Cell Renal Cell Carcinoma.
    Ricketts CJ; Crooks DR; Linehan WM
    Cancer Cell; 2016 Oct; 30(4):515-517. PubMed ID: 27728802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.